Open AccessSignificance of CSE-1034 (Elores™) in Treatment of Urinary Tract Infections due to Multi Drug Resistant ESBLPositiveEscherichia coli
Author(s) -
Vishal Bhambri
Publication year - 2016
Publication title -
asian journal of pharmaceutical and clinical research
Language(s) - English
Resource type - Journals
eISSN - 2455-3891
pISSN - 0974-2441
DOI - 10.22159/ajpcr.2016.v9i6.14409
Subject(s) - ceftriaxone , sulbactam , medicine , antibiotics , urinary system , drug resistance , escherichia coli , efflux , microbiology and biotechnology , pathogen , antibiotic resistance , intensive care medicine , biology , immunology , biochemistry , genetics , imipenem , gene
UTIs are one of the most common infections of geriatric patients in community acquired and hospital acquired settings. Escherichia coli(E. coli) is usually the most common pathogen responsible for UTI.Antibiotic resistance is the main reason for failure of therapy especially in E. coli. Biofilm formation, ESBL and MBL production&efflux pump over expression are the main reasons for antibiotic resistance in E. coli. That’s why management of UTI with multi drug resistant (MDR)E. coli has always been challenge for the clinicians.We are reporting empiric use of new antibiotic adjuvant entity Elores™(Ceftriaxone/ Sulbactam/Disodium-edetate) in the management of UTIs caused by multi drug resistant E. coli.